A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria - NCT05528861

Absolute change in weekly Urticaria Activity Score (UAS7) from baseline to Week 12, Absolute change in Hives Severity Score (HSS7) from baseline to Week 12, Absolute change in Itch Severity Scale (ISS7) from baseline to Week 12, Proportion of subjects achieving UAS7=0